home / stock / cogt / cogt news


COGT News and Press, Cogent Biosciences Inc Com From 12/11/23

Stock Information

Company Name: Cogent Biosciences Inc Com
Stock Symbol: COGT
Market: NASDAQ
Website: cogentbio.com

Menu

COGT COGT Quote COGT Short COGT News COGT Articles COGT Message Board
Get COGT Alerts

News, Short Squeeze, Breakout and More Instantly...

COGT - Veru, Kodiak Sciences among healthcare movers

2023-12-11 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Veru, Kodiak S...

COGT - Cogent slumps after mid-stage data for rare disorder therapy

2023-12-11 09:47:58 ET More on Cogent Biosciences Seeking Alpha’s Quant Rating on Cogent Biosciences Historical earnings data for Cogent Biosciences Financial information for Cogent Biosciences For further details see: Cogent slumps after mid-stage...

COGT - PPBT, ANY and FLJ among pre-market losers

2023-12-11 08:27:31 ET Losers: Cogent Biosciences ( COGT ) -31% . announces positive data from ongoing phase 2 APEX trial evaluating Bezuclastinib in patients . Purple Biotech Ltd ( PPBT ) -16% . Sphere 3D Corp ( ANY ) -14% . FLJ Group Ltd ( F...

COGT - Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose Nearly all patients achieved at least 50% improvement in key biomarkers of disease burden: serum tryptase reduction (9...

COGT - Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 100% of bezuclastinib treated patients achieved at least 50% improvement across all relevant biomarker measures, inc...

COGT - Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3K? inhibitor programs at the San Antonio Breast Cancer Symposium

Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently approved therapies Novel, H1047R mutant-selective PI3Kα inhibitor, disclosed as t...

COGT - Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting

- Event to review initial clinical data from SUMMIT Part 1a in patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) - Additional clinical data update from APEX Part 1 in patients with Advanced Systemic Mastocytosis (AdvSM) also to be reviewed WALTHAM, Mass. and BOULDER, ...

COGT - Cogent Biosciences Inc. $COGT Trading Report

2023-11-29 23:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

COGT - Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two poster presentations at the upcoming 2023 San Antonio Breast Ca...

COGT - BMRN, TWST and CHRS are among after hour movers

2023-11-17 17:01:57 ET Gainers: Cogent Biosciences ( COGT ) +3% . Erasca ( ERAS ) +3% . Vigil Neuroscience ( VIGL ) +3% . 2seventy  ( TSVT ) +2% . Twist Biosciences ( TWST ) +2% . Losers: Nkarta ( NKTX ) -5% ...

Previous 10 Next 10